Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 29

1.

Enkephalin-Fentanyl Multifunctional Opioids as Potential Neuroprotectants for Ischemic Stroke Treatment.

Islam MR, Yang L, Lee YS, Hruby VJ, Karamyan VT, Abbruscato TJ.

Curr Pharm Des. 2016 Jul 20. [Epub ahead of print]

PMID:
27510489
2.

Preparation and preliminary characterization of recombinant neurolysin for in vivo studies.

Wangler NJ, Jayaraman S, Zhu R, Mechref Y, Abbruscato TJ, Bickel U, Karamyan VT.

J Biotechnol. 2016 Sep 20;234:105-15. doi: 10.1016/j.jbiotec.2016.07.007.

PMID:
27496565
3.

Competitive Binding Assay for the G-Protein-Coupled Receptor 30 (GPR30) or G-Protein-Coupled Estrogen Receptor (GPER).

Thekkumkara T, Snyder R, Karamyan VT.

Methods Mol Biol. 2016;1366:11-7. doi: 10.1007/978-1-4939-3127-9_2.

PMID:
26585123
4.

In vitro and in vivo efficacy of a potent opioid receptor agonist, biphalin, compared to subtype-selective opioid receptor agonists for stroke treatment.

Yang L, Islam MR, Karamyan VT, Abbruscato TJ.

Brain Res. 2015 Jun 3;1609:1-11. doi: 10.1016/j.brainres.2015.03.022.

5.

Distribution of non-AT1, non-AT2 binding of 125I-sarcosine1, isoleucine8 angiotensin II in neurolysin knockout mouse brains.

Speth RC, Carrera EJ, Bretón C, Linares A, Gonzalez-Reiley L, Swindle JD, Santos KL, Schadock I, Bader M, Karamyan VT.

PLoS One. 2014 Aug 22;9(8):e105762. doi: 10.1371/journal.pone.0105762.

6.

2-methoxyestradiol binding of GPR30 down-regulates angiotensin AT(1) receptor.

Koganti S, Snyder R, Gumaste U, Karamyan VT, Thekkumkara T.

Eur J Pharmacol. 2014 Jan 15;723:131-40. doi: 10.1016/j.ejphar.2013.10.064.

7.

Functional up-regulation of endopeptidase neurolysin during post-acute and early recovery phases of experimental stroke in mouse brain.

Rashid M, Wangler NJ, Yang L, Shah K, Arumugam TV, Abbruscato TJ, Karamyan VT.

J Neurochem. 2014 Apr;129(1):179-89. doi: 10.1111/jnc.12513.

8.

Angiotensin II type 1 receptor antagonists in the treatment of hypertension in elderly patients: focus on patient outcomes.

Tadevosyan A, Maclaughlin EJ, Karamyan VT.

Patient Relat Outcome Meas. 2011 Jul;2:27-39. doi: 10.2147/PROM.S8384.

9.

Identification of membrane-bound variant of metalloendopeptidase neurolysin (EC 3.4.24.16) as the non-angiotensin type 1 (non-AT1), non-AT2 angiotensin binding site.

Wangler NJ, Santos KL, Schadock I, Hagen FK, Escher E, Bader M, Speth RC, Karamyan VT.

J Biol Chem. 2012 Jan 2;287(1):114-22. doi: 10.1074/jbc.M111.273052.

10.

Characterization of neuroprotective effects of biphalin, an opioid receptor agonist, in a model of focal brain ischemia.

Yang L, Shah K, Wang H, Karamyan VT, Abbruscato TJ.

J Pharmacol Exp Ther. 2011 Nov;339(2):499-508. doi: 10.1124/jpet.111.184127.

11.

Evidence that gamma-secretase-mediated Notch signaling induces neuronal cell death via the nuclear factor-kappaB-Bcl-2-interacting mediator of cell death pathway in ischemic stroke.

Arumugam TV, Cheng YL, Choi Y, Choi YH, Yang S, Yun YK, Park JS, Yang DK, Thundyil J, Gelderblom M, Karamyan VT, Tang SC, Chan SL, Magnus T, Sobey CG, Jo DG.

Mol Pharmacol. 2011 Jul;80(1):23-31. doi: 10.1124/mol.111.071076. Erratum in: Mol Pharmacol. 2011 Sep;80(3):550.

12.

Opioid receptor agonists reduce brain edema in stroke.

Yang L, Wang H, Shah K, Karamyan VT, Abbruscato TJ.

Brain Res. 2011 Apr 6;1383:307-16. doi: 10.1016/j.brainres.2011.01.083.

PMID:
21281614
13.

Preliminary biochemical characterization of the novel, non-AT1, non-AT2 angiotensin binding site from the rat brain.

Karamyan VT, Arsenault J, Escher E, Speth RC.

Endocrine. 2010 Jun;37(3):442-8. doi: 10.1007/s12020-010-9328-2. Erratum in: Endocrine. 2010 Oct;38(2):312.

14.

Association of the novel non-AT1, non-AT2 angiotensin binding site with neuronal cell death.

Rashid M, Arumugam TV, Karamyan VT.

J Pharmacol Exp Ther. 2010 Dec;335(3):754-61. doi: 10.1124/jpet.110.171439.

15.

Evidence that adiponectin receptor 1 activation exacerbates ischemic neuronal death.

Thundyil J, Tang SC, Okun E, Shah K, Karamyan VT, Li YI, Woodruff TM, Taylor SM, Jo DG, Mattson MP, Arumugam TV.

Exp Transl Stroke Med. 2010 Aug 11;2(1):15. doi: 10.1186/2040-7378-2-15.

16.

Distribution of a novel binding site for angiotensins II and III in mouse tissues.

Rabey FM, Karamyan VT, Speth RC.

Regul Pept. 2010 Jun 8;162(1-3):5-11. doi: 10.1016/j.regpep.2010.02.007.

PMID:
20171994
17.

Design, synthesis, and docking studies of novel benzimidazoles for the treatment of metabolic syndrome.

Mizuno CS, Chittiboyina AG, Shah FH, Patny A, Kurtz TW, Pershadsingh HA, Speth RC, Karamyan VT, Carvalho PB, Avery MA.

J Med Chem. 2010 Feb 11;53(3):1076-85. doi: 10.1021/jm901272d.

PMID:
20073471
18.

Pivotal role for beta-1 integrin in neurovascular remodelling after ischemic stroke.

Lathia JD, Chigurupati S, Thundyil J, Selvaraj PK, Mughal MR, Woodruff TM, Chan SL, Karamyan VT, Mattson MP, Arumugam TV.

Exp Neurol. 2010 Jan;221(1):107-14. doi: 10.1016/j.expneurol.2009.10.007.

PMID:
19837065
19.

Brain AT1 angiotensin receptor subtype binding: importance of peptidase inhibition for identification of angiotensin II as its endogenous ligand.

Karamyan VT, Gadepalli R, Rimoldi JM, Speth RC.

J Pharmacol Exp Ther. 2009 Oct;331(1):170-7. doi: 10.1124/jpet.109.157461.

20.

Human brain contains a novel non-AT1, non-AT2 binding site for active angiotensin peptides.

Karamyan VT, Stockmeier CA, Speth RC.

Life Sci. 2008 Sep 12;83(11-12):421-5. doi: 10.1016/j.lfs.2008.07.003.

Items per page

Supplemental Content

Loading ...
Support Center